VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 28, 2008) - Tekmira Pharmaceuticals Corporation (“Tekmira”) (TSX: TKM) announced today that a new second-generation formulation of the Company’s liposomal drug delivery technology has the potential to bring a 10-fold increase in potency to RNA interference (RNAi) drugs that are administered intravenously.
